| Frederik A Pennings, MD, PHD | |
|
119 Belmont St, Worcester, MA 01605-2903 | |
| (508) 334-1886 | |
| (508) 334-9769 |
| Full Name | Frederik A Pennings |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 29 Years |
| Location | 119 Belmont St, Worcester, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215126479 | NPI | - | NPPES |
| 2148056 | Medicaid | MA | |
| 110078576A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 234128 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holyoke Medical Center | Holyoke, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holyoke Medical Center Inc | 2163419383 | 122 |
News Archive
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.
Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.
Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.
› Verified 7 days ago
| Entity Name | Baystate Medical Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548205909 PECOS PAC ID: 5991602971 Enrollment ID: O20040225000080 |
News Archive
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.
Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.
Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.
› Verified 7 days ago
| Entity Name | Holyoke Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750395737 PECOS PAC ID: 2163419383 Enrollment ID: O20040429000312 |
News Archive
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.
Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.
Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.
› Verified 7 days ago
| Entity Name | Mercy Specialist Physicians, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558500462 PECOS PAC ID: 4688721970 Enrollment ID: O20090401000487 |
News Archive
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.
Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.
Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.
› Verified 7 days ago
| Entity Name | Riverbend Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841651197 PECOS PAC ID: 5698064343 Enrollment ID: O20160614001710 |
News Archive
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.
Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.
Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Frederik A Pennings, MD, PHD 175 Carew St, Ste 300, Springfield, MA 01104-2478 Ph: (413) 452-6650 | Frederik A Pennings, MD, PHD 119 Belmont St, Worcester, MA 01605-2903 Ph: (508) 334-1886 |
News Archive
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
For Nukepills.com, specialists in the niche market of radiation emergency preparedness, 2009 was a year of record sales due to events such as Iran's nuclear program, nuclear plant radiation leaks, Potassium Iodide distribution programs and worries of dirty bombs.
Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.
Sistemic today announced immediate availability new SistemRNA product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets.
› Verified 7 days ago
Dr. Stephen M Gutting, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-334-0605 | |
Oguz I Cataltepe, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Department Of Neurosurgery, Worcester, MA 01655 Phone: 508-334-0605 Fax: 508-856-5074 | |
Dr. Madhav Sukumaran, MD, PHD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 55 Lake Avenue North, Worcester, MA 01655 Phone: 508-334-0605 | |
Richard P Moser, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Department Of Surgery, Worcester, MA 01655 Phone: 508-334-0605 Fax: 508-856-5074 | |
Arno S. Sungarian, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 67 Belmont St, Worcester, MA 01605 Phone: 508-752-6381 Fax: 508-795-0407 | |
Farid Hamzei-sichani, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Lake Ave N, Worcester, MA 01655 Phone: 508-334-0605 Fax: 508-856-5074 |